Cargando…
Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs). Immunosuppressive medication is the main therapeutic approach to reducing inflammation of the gastrointestinal tract. Immunocompromised patients are more vulnerable to severe courses of illness after infection wit...
Autores principales: | Tepasse, Phil-Robin, Vollenberg, Richard, Nowacki, Tobias Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620225/ https://www.ncbi.nlm.nih.gov/pubmed/34833096 http://dx.doi.org/10.3390/life11111220 |
Ejemplares similares
-
Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study
por: Vollenberg, Richard, et al.
Publicado: (2022) -
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
por: Vollenberg, Richard, et al.
Publicado: (2023) -
The Role of Carrageenan in Inflammatory Bowel Diseases and Allergic Reactions: Where Do We Stand?
por: Borsani, Barbara, et al.
Publicado: (2021) -
Optimising inflammatory bowel disease surveillance and dysplasia management—Where do we stand?
por: Al Bakir, Ibrahim, et al.
Publicado: (2022) -
Where Do We Stand?
Publicado: (1891)